NCT02157636已完成1 期
A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma
Constellation Pharmaceuticals0 个研究点目标入组 30 人开始时间: 2014年7月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 主要终点
- Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment
研究概览
简要总结
Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults (aged ≥ 18 years)
- •Histologically or cytologically confirmed diagnosis of multiple myeloma that has progressed despite at least one line of standard therapy
- •Must have measurable disease, defined by one or more of following: (i) a serum M protein > 0.5 g/dl measured by serum protein electrophoresis; (ii) urinary M protein excretion > 200 mg/24 hours; (iii) serum free light chain (FLC) measurement > 10 mg/dl, provided that the serum FLC ratio is abnormal
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- •Adequate hematological, renal, hepatic, and coagulation laboratory assessments
- •Written informed consent to participate in this study before the performance of any study-related procedure
排除标准
- •Current infection with HIV, Hepatitis B or Hepatitis C
- •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of CPI-0610, including any unresolved nausea, vomiting, or diarrhea that is CTCAE grade >1
- •Impaired cardiac function or clinically significant cardiac diseases, including any of the following:
- •Acute myocardial infarction or angina pectoris ≤ 6 months prior to starting study drug
- •Serum cardiac troponin (cTn) level ≥ 99% percentile of the upper reference limit
- •QTcF > 470 msec on the screening ECG
- •Left ventricular ejection fraction (LVEF) < 50%
- •Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded.)
- •Any other concurrent severe and/or uncontrolled concomitant medical condition that could compromise participation in the study (e.g., clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection)
- •Systemic anti-cancer treatment or radiotherapy less than 2 weeks before the first dose of CPI-0610
- •Treatment with an investigational small molecule less than 2 weeks before the first dose of CPI-
- •In addition, the first dose of CPI-0610 should not occur before a period equal to or greater than 5 half-lives of the small molecule investigational agent has elapsed
- •Treatment with a therapeutic antibody less than 4 weeks before the first dose of CPI-
- •A minimum 2-week period between the last treatment with a therapeutic antibody and the first dose of CPI-0610 may be permitted in patients with rapidly progressive myeloma, following discussion with the medical monitor
- •Treatment with medications that are known to be strong inhibitors or inducers of CYP450 enzymes
- •Treatment with medications that are known to carry a risk of Torsades de Pointes
- •Immunosuppressive treatment that cannot be discontinued both prior to study entry and for the duration of the study. Oral prednisone at a dose of 10 mg or less per day is allowed, as are other oral corticosteroids given at glucocorticoid-equivalent doses. Topical, nasal and inhaled corticosteroids are also allowed
- •Pregnant or lactating women
- •Women of child-bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafter
- •Patients unwilling or unable to comply with the study protocol
研究组 & 干预措施
CPI-0610
Experimental
干预措施: CPI-0610 (Drug)
结局指标
主要结局
Frequency of dose-limiting toxicities (DLTs) associated with CPI-0610 administration during the first cycle (first 21 days) of treatment
时间窗: DLTs asessed during Cycle 1 (first 21 days on study)
次要结局
- Pharmacokinetic parameters of CPI-0610: AUC(0-t), AUC(0-inf), AUCtau,ss, Tmax, Cmax, Ctrough, T1/2, Vd/F, CL/F(Assessed during cycle 1 (first 21 days on study); and on cycle 2, day 1)
- Safety and tolerability of CPI-0610 as assessed by: frequency of adverse events and serious adverse events; changes in hematology and clinical chemistry values; changes in physical examination, vital signs, electrocardiogram, ECHO and ECOG score(Assessed from Day 1 of Cycle 1 through 30 days after patient's last dose of study drug)
- Pharmacodynamic effects of CPI-0610: Changes in the expression of MYC and other genes in malignant tumor cells; changes in cellular proliferation and in the extent of apoptosis(Assessed during cycle 1 (first 21 days on study); and on cycle 2, day 1)
- Changes in the expression of a set of genes in peripheral blood mononuclear cells (PBMCs) that are sensitive to BET inhibition(Assessed during cycle 1 (first 21 days on study))
- Anti-myeloma activity associated with CPI-0610 treatment(Assessed after every cycle of treatment; assessed up to approximately 12 months)
研究者
相似试验
已完成
1 期
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive LymphomaLymphomaNCT01949883Constellation Pharmaceuticals64
已完成
1 期
A Study Evaluating CPI-1205 in Patients With B-Cell LymphomasB-Cell LymphomaNCT02395601Constellation Pharmaceuticals41
已完成
1 期
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic CancerAcinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic CancerNCT01835041Wake Forest University Health Sciences21
撤回
2 期
Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath TumorsPeripheral Nerve TumorsNCT02986919University of Texas Southwestern Medical Center
已完成
1 期
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative MalignanciesLeukemia, Myelocytic, AcuteMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic Syndrome (MDS)PreleukemiaMyeloproliferative DisordersBone Marrow DiseaseHematological DiseasePrecancerous ConditionsNeoplasmsNeoplasms by Histologic TypeEssential ThrombocytosisLeukemiaMyelofibrosisPrimary MyelofibrosisNCT02158858Constellation Pharmaceuticals336